United States News All stories

A Massachusetts court has blocked Kalshi from offering sports betting to residents amid legal action by the state.

Delaware Life has added Bitcoin-linked exposure to its retirement annuity portfolio via a BlackRock-developed index.

Coinbase says wealth creation increasingly depends on access to capital markets rather than income or traditional banking.

WLFI is under fire after team wallets pushed through a USD1 proposal while many locked holders were unable to vote.

European regulators in Hungary and Portugal have taken steps to block Polymarket, intensifying scrutiny of crypto prediction markets.

Messari warns that without KYC checks, insider trading on prediction markets is extremely difficult to prevent.

Japan’s bond market has been sliding all week, with the 10-year yield now near 2.37% and the 40-year pushing above 4.2%, both multi-decade highs.

Bristol Myers Squibb (NYSE:BMY) has partnered with Microsoft (NASDAQ:MSFT) to deploy artificial intelligence tools aimed at identifying lung cancer in its earliest stages, marking the latest push by a pharmaceutical giant to integrate big tech’s machine learning into clinical care.

D.R. Horton (NYSE:DHI) reported first-quarter results that surpassed Wall Street expectations on Tuesday, even as the nation's largest homebuilder grapples with a persistent "wait-and-see" attitude from buyers.

United Airlines Holdings (NYSE:UAL) shares took flight in after-hours trading Tuesday after the carrier posted the highest quarterly revenue in its history, overcoming a costly government shutdown to deliver a significant earnings beat.

Netflix (NASDAQ:NFLX) shares dipped in after-hours trading Tuesday despite the streaming giant beating revenue expectations and crossing the 325-million subscriber milestone, as investors weighed the massive financial commitments of its pending Warner Bros. Discovery acquisition.

A broad selloff erased billions in market value Tuesday as investors retreated from high-flying technology stocks, spooked by President Trump’s escalating trade war threats against European allies.

Corvus Pharmaceuticals (NASDAQ:CRVS) shares skyrocketed more than 60% in early trading Tuesday after the company reported that its experimental oral therapy significantly cleared skin in patients with moderate-to-severe atopic dermatitis.

Viatris (NASDAQ:VTRS) has officially commenced the global expansion of its cardiovascular portfolio with the launch of Inpefa (sotagliflozin) in the United Arab Emirates, marking the first commercial availability of the therapy outside the United States.

MAIA-BIOTECH-2026-CLINICAL-OUTLOOK

Performance Shipping (NASDAQ:PSHG) secured a three-year charter agreement with PBF Energy, pushing its revenue backlog to an all-time high and reinforcing its strategy of locking in long-term cash flow amid a volatile global energy market.

Barnes & Noble Education (NYSE:BNED) shares rose Tuesday after the campus bookstore operator reported a return to profitability for its fiscal second quarter, driven by aggressive growth in its inclusive-access course material programs.

Phio Pharmaceuticals (NASDAQ:PHIO) reported that its experimental gene-silencing therapy cleared tumors in the majority of patients during a mid-stage study, marking a significant win for its proprietary INTASYL technology.

MSC Income Fund (NYSE:MAIN) signaled a strong finish to 2025, providing preliminary fourth-quarter results that point to rising asset values and double-digit returns on equity as it navigates a stabilizing interest rate environment.

ZOOZ Strategy (NASDAQ:ZOOZ) finished 2025 with a significantly bolstered balance sheet and a clean debt profile, reflecting the company’s aggressive transition from energy storage to a Bitcoin-anchored holding company.

Corporación América Airports (NYSE:CAAP) reported robust passenger growth for 2025, fueled by a surge in international travel and record-breaking performances in key markets.

Regentis Biomaterials (NYSE:RGNT) shares gained after new long-term imaging data showed its hydrogel implant successfully regenerated knee cartilage with a structural complexity nearly identical to healthy human tissue.

Celcuity (NASDAQ:CELC) shares rose in premarket trading Tuesday after the U.S. Food and Drug Administration accepted the New Drug Application for gedatolisib, a potential first-in-class therapy for patients with advanced breast cancer.

Dyne Therapeutics (NASDAQ:DYN) secured a regulatory win in Asia as Japanese authorities granted orphan drug status to its lead candidate for myotonic dystrophy, providing the biotech with a clear path toward market exclusivity in the world’s third-largest pharmaceutical market.